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Gene expression in the gut is segmentally regulated, but little is known of the molecular origin of patterning.
Analysis of gene expression in colons from mice lacking the methyl-CpG binding repressor MBD2 revealed
frequent activation of genes that are normally only expressed in the exocrine pancreas and duodenum. Reduced
DNA methylation activated the same gene set in the colon. No significant differences in DNA methylation
between the colon and duodenum were detected, but MBD2 was significantly more abundant in the colon. The
relevance of MBD2 concentration was tested in a human colon cancer cell line. Depletion of MBD2 was again
found to activate exocrine pancreatic genes. Gene activation in this cell culture model was accompanied by loss
of promoter-bound MBD2 and increased histone acetylation. The results suggest that modulation of MBD2
during gut development establishes a region-specific gene expression pattern that is essential for establishing
correct segmental character.
CpG methylation plays a role in long-term gene silencing
such as X inactivation and imprinting, but its role in differen-
tiation of specialized cells and organogenesis is less well doc-
umented. An understanding of the involvement of DNA meth-
ylation in development can be gained by functional studies of
methyl-CpG-binding proteins (MBPs), which mediate down-
stream effects by binding to methylated DNA and recruiting
protein partners (12, 17). MBPs fall into two families: the
MBD proteins, MBD1, MBD2, MBD4, and MeCP2, which
share a related 80-amino-acid methyl-CpG binding domain
(10), and the Kaiso-like proteins, Kaiso, ZBTB4, and ZBTB38,
which bind DNA methylated at CpGs via a conserved zinc-
finger motif (9, 27). Biochemical analysis of MeCP2, MBD1,
MBD2, and Kaiso has provided evidence that each can asso-
ciate with a specific corepressor complex and bring about
transcriptional silencing in model gene expression systems.
The present study concerns MBD2, which is a transcrip-
tional repressor that can be isolated in a complex with com-
ponents of the NuRD complex, including the SNF2-like motor
protein Mi-2 and histone deacetylases (8, 22, 26, 34). MBD2 is
the only member of the MBD protein family to be represented
by invertebrate orthologs (12). Evidence for the involvement of
MBD2 in differentiation and development has come from
mouse genetics. Mice in which the Mbd2 gene is deleted are
viable and fertile (11), but they mis-express the interleukin 4
and interferon  genes in T helper (TH) cells (13). Expression
of the interferon  and interleukin 4 genes is mutually exclusive
in the TH1 and TH2 derivatives of wild-type naive TH cells, but
Mbd2/ TH cells often expressed both genes simultaneously.
Failure to adequately repress these genes in differentiated TH1
and TH2 cells alters the immune response in MBD2-deficient
animals (14). Also, aberrant derepression of human fetal glo-
bin genes in Mbd2-null mice bearing a transgene that contains
the human -like globin gene cluster has also been reported
(31). In addition to these examples of gene misregulation, it
has been found that depletion of MBD2 greatly reduces the
number of intestinal adenomas in tumor-prone ApcMin mice
(32). Although the molecular basis of this effect is unknown, it
may be relevant that MBD2 is required for silencing of specific
tumor-suppressor genes in human colorectal carcinoma cells
and in other human cancer cell lines (3, 24). MBD2-mediated
repression of tumor suppressor genes may therefore be a pre-
requisite for tumor formation, although other explanations
cannot currently be ruled out.
In the present study we investigated gene expression in the
colons of Mbd2/ mice. We found that a set of genes coding
for digestive enzymes normally expressed only in duodenum
and pancreas are highly overexpressed in the Mbd2-null colon,
the level of overexpression being variable between individual
mice. DNA methylation profiles were indistinguishable be-
tween wild-type duodenum and colon, but MBD2 was 5-fold
more abundant in colon. The MBD2-deficient phenotype
could be mimicked in human colorectal carcinoma cells by
depletion of MBD2 or DNA methylation, leading to overex-
pression and altered chromatin structure at these genes. Our
results establish that a stable gene expression pattern in the
mature gut is dependent on DNA methylation and MBD2.
MATERIALS AND METHODS
Mice and tissue samples. Mbd2/ mice (11) are kept as inbred homozygous
lines on a C57BL/6 and a BALB/c background. Dnmt1c/ mice (23) are kept on
a C57BL/6 background.
Cell lines. HCT116 cells were obtained from the American Type Culture
Collection. DKO cells were a gift from B. Vogelstein. Both cell lines were
maintained in RPMI medium containing 10% (vol/vol) fetal calf serum. For
HDAC inhibition, cells were treated with 500 nM trichostatin A (Sigma) for 18 h.
MBD2 siRNA and shRNA. Two different predesigned small interfering RNAs
(siRNAs) directed against MBD2 (ID no. 14015 and ID no. 13925) were pur-
chased from Ambion. Both siRNAs (150 pmol each) were cotransfected three
times at 24-h intervals into HCT116 cells using Oligofectamine (Invitrogen).
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Silencer negative control siRNA#1 (Ambion) was used as a control. To generate
the small hairpin RNA (shRNA) vector, a 64-bp hairpin sequence directed
against MBD2 was cloned into the pSuper vector with puromycin resistance.
Stable cell clones were obtained after puromycin selection.
Real-time RT-PCR. Total RNA was extracted from mouse intestines using
RNA-Bee (Tel-Test) and cultured cells using TriReagent (Sigma) according to
the manufacturer’s instructions. After DNase treatment with DNA-Free (Am-
bion), cDNA was transcribed using Moloney murine leukemia virus reverse
transcriptase (Promega). Real-time PCR was carried out with iQ SYBR Green
Supermix (Bio-Rad) on an iCycler (Bio-Rad) according to the manufacturer’s
instructions. The primer sequences used for reverse transcription-PCR (RT-
PCR) can be obtained on request.
Western blotting and immunohistochemistry. Approximately 100 mg of snap-
frozen mouse intestine was placed into 600 l of Laemmli buffer (60 mM
Tris-HCl, 100 mM dithiothreitol, 10% glycerol, 2% sodium dodecyl sulfate
[SDS]), sonicated for 15 s, and boiled for 6 min. After spinning for 4 min at
14,000 rpm (4°C), the supernatant was run on a polyacrylamide gel. Western blot
analyses with protein extracts from mouse tissue or cultured human cells were
performed using standard protocols. Rabbit R593 anti-MBD2 antiserum (26)
was used to probe the blots. Immunohistochemistry was performed on 5-m
cryosections fixed in 4% paraformaldehyde. After the sections were boiled in 10
mM citric acid (pH 6.0) for 5 min, staining was performed using the Mouse-on-
Mouse peroxidase kit (Vector Laboratories) according to the manufacturer’s
instructions. A mouse monoclonal antibody (anti-human spasmolytic polypep-
tide, catalog no. NCL-HSP; Novocastra) was used to detect TFF2 (spasmolytic
polypeptide).
Chromatin immunoprecipitation (ChIP). Cells were grown until confluent,
cross-linked in 1% formaldehyde in phosphate-buffered saline (PBS) for 10 min,
washed in PBS, and lysed in lysis buffer (1% SDS, 10 mM EDTA, 50 mM
Tris-HCl [pH 8.0]). The chromatin was sonicated for 3 min at 35% amplitude
using a digital sonifier (Branson) and then diluted 1:10 in immunoprecipitation
dilution buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl
[pH 8.0]). After the samples were precleared for 2 h with salmon sperm DNA-
bovine serum albumin-protein G-Sepharose beads, 15 g of affinity-purified
anti-MBD2 antiserum (S923 [26]), anti-acetyl histone H4 antibody (catalog no.
06 to 598, Upstate), or unrelated control antibodies were added to each sample,
followed by rotation overnight at 4°C. To collect the immunocomplexes, 100 l
of protein G-Sepharose was added to the samples for 1 h at 4°C. The beads were
then washed once in buffer 1 (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 150
mM NaCl, 20 mM Tris-HCl), four times in buffer 2 (0.1% SDS, 1% Triton X-100,
2 mM EDTA, 500 mM NaCl, 20 mM Tris-HCl), once in buffer 3 (250 mM LiCl,
1% NP-40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCl), and twice in TE
buffer (10 mM Tris-HCl, 1 mM EDTA). Immunocomplexes were then eluted
with 2 100 l of extraction buffer (1% SDS, 100 mM NaHCO3), and cross-links
were reversed by adding 5 M NaCl to a final concentration of 300 mM, followed
by incubation at 65°C overnight. The primer sequences for amplification of the
TFF2 promoter can be obtained on request.
Bisulfite genomic sequencing. DNA was phenol-chloroform extracted from
cultured cells or mouse intestine after proteinase K digestion. DNA (2 g) was
bisulfite modified and PCR amplified (primer sequences are available on re-
quest). PCR products were gel purified and cloned using the TOPO TA cloning
kit (Invitrogen). Colonies for each PCR (10–14) were picked for sequencing.
Global DNA methylation analysis. Decreasing amounts of DNA were slot
blotted onto a nitrocellulose membrane and then incubated with recombinant
protein consisting of four sequential hemagglutinin (HA)-tagged methyl-CpG-
binding domains of MBD1, which can bind to methylated but not unmethylated
DNA (16). Incubation with an anti-HA antibody allowed visualization and quan-
tification of the amount of methylated DNA in the sample. M.Sss1-methylated
DNA and DNA isolated from bacteriophage lambda were used as positive and
negative controls, respectively, for CpG methylation.
RESULTS
ExPa genes are activated in colons of Mbd2-null and
Dnmt1-deficient mice. As part of our investigations concerning
the resistance of Mbd2-null mice to intestinal tumorigenesis
(32), we examined gene expression patterns in colons from
wild-type and Mbd2-null mice by using Affymetrix gene expres-
sion microarrays. A group of genes stood out as highly over-
expressed (30-fold) specifically in Mbd2-null colons (Table 1;
see the Affymetrix data set in the supplemental material). We
noted that other members of the MBD family—MBD1,
MBD4, and MeCP2—were not transcriptionally upregulated
in the absence of MBD2 (see the Affymetrix data set in the
supplemental material). The overexpressed genes predomi-
nantly encode digestive enzymes that are expressed in the
exocrine pancreas and duodenum and secreted into the duo-
denum, where they enzymatically degrade nutrients. These
genes are normally silent in the colon, whose main function is
water and salt resorption (7). To verify the microarray results, we
analyzed expression of six exocrine pancreatic (ExPa) genes in the
colons of 9 wild-type and 13 Mbd2-null BALB/c mice using quan-
titative RT-PCR (Fig. 1A). We excluded amylase 1 from the
analysis because it is also expressed at significant levels in wild-
type colon (data not shown). Surprisingly, significant overexpres-
sion of these genes was seen in only 7 of 13Mbd2-deficient colons:
an apparent penetrance of 50%. Levels of overexpression also
varied widely, with some animals expressing 10,000-fold more
than the basal levels in wild-type colon. The results demonstrate
a continuum of overexpression in the absence of MBD2.
Several considerations argue that phenotypic variability is
not genetic in origin. First, these mice were back-crossed for
eight generations onto a BALB/c genetic background. Second,
incomplete penetrance was independent of genetic back-
ground, since four of eight Mbd2-null mutants that had been
back-crossed onto a C57BL/6 background (eight generations)
showed derepression of ExPa genes (Fig. 1B). Third, signifi-
cant heterogeneity arose between siblings, since only two of
four adult littermates (one male and one female) showed ex-
pression of the ExPa genes in colon (data not shown). We also
considered the possibility that the activation of ExPa genes
correlated positively or negatively with postnatal age, but no
correlation was seen between ExPa gene overexpression and
postweaning age (data not shown). Importantly, two of four
newborn (postnatal day 4) Mbd2-null mice showed upregula-
tion of ExPa enzymes in the colon (Fig. 1C), indicating that the
incomplete penetrance of ExPa gene expression is present
soon after birth in the Mbd2-null mouse colon.
Differentiation of the exocrine pancreas is under the control
of the transcription factor complex Ptf1, which comprises two
widely expressed proteins, p64 and p75, plus the highly tissue
specific factor p48 (19, 20, 30). Mice carrying a disrupted p48
gene specifically lack an exocrine pancreas (30). We sought to
determine whether the overexpression of ExPa genes corre-
TABLE 1. ExPa genes found to be strongly upregulated in the
Mbd2-null colon by Affymetrix gene expression microarray
Gene Description UniGeneaccession no.
GenBank
accession no.
Fold
upregulation
in Mbd2/
colon
Amy1 Amylase 1 Mm.378882 X02578 2,084
Prss2 Serine protease 2 Mm.276926 X04574 267
Reg2 Regenerating
islet-derived 2
Mm.46360 D14011 99
Ela2 Elastase 2 Mm.45316 X04573 71
Rib1 Pancreatic
RNase 1
X60103 60
Tff2 Trefoil factor 2 Mm.1825 U78770 52
Cel Carboxyl ester
lipase
Mm.236017 U37386 32
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lated with p48 mis-expression in MBD2-deficient colons. The
results showed a strong correlation, since p48 expression was
confined to colons that also overexpressed the pancreas-spe-
cific gene set (Fig. 1A). Derepression of p48 may therefore
trigger the overexpression phenotype. We also tested the ex-
pression of Cdx1 and Cdx2, which are required for anterior-
posterior patterning and the development of the intestinal
epithelium. No significant difference in mRNA levels between
wild-type and Mbd2-null colons was observed (data not
shown).
To determine which regions of the Mbd2-null intestine over-
express ExPa genes, we isolated RNA from the colon and the
three segments comprising the small intestine: the duodenum,
the jejunum, and the ileum. Real-time RT-PCR revealed that
ExPa genes are, as expected, expressed in the duodenum in
wild-type mice (Fig. 1D). In Mbd2-null mice, aberrant expres-
sion of digestive enzymes was only observed in the colon, since
the jejunum and ileum were not affected. At their highest, the
expression levels of p48, Tff2, and Ela2 in the colons of Mbd2-
deficient mice were comparable to levels seen in the duode-
num. We next sought to determine whether variable ExPa gene
expression in Mbd2-null mice was caused by different numbers
of expressing cells per colon or different levels of expression in
a constant set of cells. Strong cytoplasmic immunostaining for
TFF2 was observed in goblet cells and enterocytes in two of
five Mbd2-null mouse colons (Fig. 1E and data not shown).
One ExPa-expressing colon showed TFF2 expression in mul-
tiple cells in adjacent crypts (Fig. 1E, middle panel), whereas in
the other mouse strong staining was only seen in single cells in
a small fraction of crypts (Fig. 1E, top panel). No TFF2-
positive crypt cells were seen in five wild-type mouse colons
(Fig. 1E, bottom panel, and data not shown). Variability of
expression levels in Mbd2-deficient mice may therefore be due
to different numbers of crypt cells that escape ExPa gene
repression.
Since MBD2 is reported to read the DNA methylation
signal, we speculated that reduced levels of DNA methyl-
ation would also induce inappropriate expression of the
FIG. 1. Expression of ExPa genes in wild-type and Mbd2/ mice. (A) Real-time quantitative RT-PCR analysis of ExPa gene expression in the
colon of nine wild-type and 13 Mbd2-null BALB/c mice. Each horizontal row corresponds to one mouse. Values represent the fold overexpression
of genes normalized to average expression in wild-type samples. (B) The partial penetrance of ExPa gene overexpression is independent of the
mouse strain. Detection of ExPa gene expression levels in the colon of eight wild-type and eight Mbd2-null C57BL/6 mice by real-time RT-PCR
as in panel A. (C) ExPa gene expression levels in colons isolated from 4-day-old BALB/c wild-type and Mbd2-null mice. The expression levels were
analyzed by real-time RT-PCR and were normalized to the average expression in wild-type samples. (D) Real-time RT-PCR analysis for expression
patterns of ExPa genes in four intestinal segments (Duo, duodenum; Jej, jejunum) of wild-type and Mbd2-null mice. Overexpression levels are
calculated compared to the levels in the wild-type colon. (E) Immunohistochemical detection of TFF2 in colonic epithelium of Mbd2-null mice (top
and middle panels) and wild-type mice (bottom panel). Positively stained enterocytes (brown spots; white arrows show examples) and goblet cells
are only seen in mutant crypts.
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same genes. Absence of the maintenance DNA methyltrans-
ferase DNMT1 is lethal in mice (23), but phenotypic effects
on cancer susceptibility have been observed in Dnmt1/
heterozygotes, suggesting that reducing the amount of en-
zyme by half affects DNA methylation (21). To test for the
effects of heterozygosity of the Dnmt1c allele on DNA meth-
ylation levels, we carried out bisulfite genomic sequencing of
a region upstream of the Tff2 promoter. Average DNA
methylation across the region was significantly less in
Dnmt1c/ heterozygotes than in wild-type mice (61% versus
38%; Fig. 2A). When the expression of ExPa genes was
examined in Dnmt1c/ mice, we observed overexpression of
the ExPa genes in 4 of 15 mice (Fig. 2B). As in the case of
Mbd2-null mice, Dnmt1 deficiency increased the probability
that colon cells escape the repression of ExPa genes that
normally prevails in this organ.
MBD2 abundance controls ExPa gene expression. The ge-
netic results show that deficiency of either DNA methylation
or of a protein that binds to methylated DNA causes gene
activation specifically in the colon. Targeting of transcriptional
silencing to the colon may be due to higher levels of CpG
methylation or a higher abundance of MBD2 in distal regions
of the intestinal tract. We first examined global DNA methyl-
ation levels using as an assay the binding of a poly-MBD
domain reagent that provides a semiquantitative measure of
CpG methylation (16). No difference was observed between
colon and duodenum (Fig. 3A). Detailed analysis of two re-
gions of the Tff2 gene promoter also showed levels of CpG
methylation that were not significantly different between the
colon and the duodenum (61% versus 59% methylation, re-
spectively, across a total of 16 CpG sites; Fig. 3B). Analysis of
the p48 gene established the presence of a CpG island that is
nonmethylated in duodenum, colon, and leukocyte DNA. We
tested CpG methylation in the upstream “negative regulatory
domain” of p48, including a conserved region 2 to 4 kb up-
stream of the transcription start site that has been implicated
in silencing of p48 (18, 30). CpG methylation was detected, but
again, no consistent differences between the colon and the
duodenum were observed (Fig. 3C).
In contrast to the apparent constancy of DNA methylation,
the concentration of MBD2 was 5-fold higher in the colon
than in the duodenum as determined by Western blot analysis
when normalized against GAPDH (glyceraldehyde-3-phos-
phate dehydrogenase) protein (Fig. 3D). Levels of MBD2 in
the ileum and jejunum, where ExPa genes are also silent, were
likewise higher than in the duodenum and were similar to
colon levels (Fig. 3D). We only detected the larger MBD2a
isoform with antibodies that detect both MBD2a and MBD2b,
suggesting that MBD2b is a rare form in this tissue (data not
shown). The relative abundance of MBD2 in the colon is com-
patible with the hypothesis that various concentrations of this
CpG methylation-dependent repressor contribute to the con-
trol of differential gene expression in colon and duodenum. To
test this idea, we sought to determine whether expression of
the ExPa genes is affected by artificial modulation of MBD2
concentrations in a model system: the human colon cancer cell
line HCT116. We depleted MBD2 by stably expressing an
shRNA directed against MBD2 mRNA. Real-time RT-PCR
showed an mRNA knockdown of more than 90% in two
shRNA-expressing clones (Fig. 4A), and Western blot analysis
confirmed almost complete depletion of both MBD2a and
MBD2b isoforms (Fig. 4B). This treatment caused 10-fold
overexpression of two digestive enzymes, encoded by the genes
TFF2 and CEL, in both MBD2-depleted cell clones (Fig. 4C).
A more modest downregulation of MBD2 that paralleled the
5-fold difference between mouse duodenum and colon was
achieved by transfecting siRNAs targeted against MBD2
mRNA (Fig. 4D and E) and once again led to 10-fold up-
regulation of TFF2 and CEL gene expression (Fig. 4F). There-
fore, the modulation of MBD2 levels is sufficient to regulate
the expression of these genes in a human colon cell line. We
also tested the effects of DNA hypomethylation on these
genes, using a DNMT1/, DNMT3b/ double mutant deriv-
ative of HCT116 cells (28). The double-knockout (DKO) cells
FIG. 2. Aberrant expression of ExPa genes in the colons of Dnmt1c/ mice. (A) Bisulfite genomic sequencing of the mouse Tff2 promoter region
in the colon of wild-type and Dnmt1c/ C57BL/6 mice. CpGs are represented by vertical lines. Brackets show PCR products amplified after bisulfite
treatment. Empty circles represent unmethylated cytosine residues, and filled circles represent methylated cytosine residues. (B) Real-time
RT-PCR analysis of ExPa gene expression in wild-type and Dnmt1c/ C57BL/6 mouse colons. Each horizontal row corresponds to one mouse.
Values correspond to the fold overexpression of genes normalized to average expression in wild-type samples.
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carry mutations in the DNA methyltransferases DNMT1 and
DNMT3b and show reduced DNA methylation levels, as mon-
itored by bisulfite sequencing (Fig. 5A). We detected 10-fold
upregulation of TFF2 and P48 and 4-fold overexpression of
CEL in DKO cells (Fig. 5B), indicating that DNA methylation,
like MBD2, plays a role in silencing these genes.
We noticed that P48, RIB1, and ELA2 were not upregulated
in MBD2-deficient HCT116 cells in contrast to Mbd2-null
mouse colon. Since P48 is an upstream activator of ExPa
genes, we investigated the reason for its silence. Bisulfite se-
quencing established that the promoter CpG island of human
P48 is densely methylated in these cells, although this region is
nonmethylated in human blood DNA (Fig. 5C). Most CpG
islands are nonmethylated regardless of gene expression (1),
but their aberrant methylation, particularly at tissue specifi-
cally expressed genes, is a common feature of cancer cells (15)
and other permanent cell lines (2, 5), where it effectively si-
lences the associated genes. The inference that P48 is silenced
by aberrant methylation in HCT116 cells is supported by its
induction in a DNA methylation-deficient derivative of the
same line (Fig. 5B). Parenthetically, it is apparent from these
results that P48 silencing due to aberrant methylation of its
CpG island promoter in HCT116 cells is not primarily medi-
ated by MBD2.
MBD2 binding and deacetylation of repressed exocrine pan-
creatic genes. To test whether TFF2 is a direct MBD2 target,
we carried out ChIP in wild-type, MBD2-depleted, and DNA
methylation-deficient HCT116 cells. ChIP of genomic DNA
corresponding to three primer pairs covering 1 kb upstream
of the transcription start site was assayed by quantitative PCR.
MBD2 was enriched at the TFF2 promoter in wild-type
HCT116 cells, but binding to a domain extending 1 kb up-
stream of the transcription start site (Fig. 6A) was reduced by
both MBD2-shRNA treatment and in DKO derivative cells
(Fig. 6B). A similar reduction in MBD2 occupancy was ob-
served at the P48 promoter in MBD2-deficient and DKO
HCT116 cells (data not shown). Since MBD2 is known to
recruit HDACs associated with the NuRD complex, we sought
to determine whether reduced MBD2 binding was accompa-
nied by an increase in histone acetylation levels at the TFF2
promoter. ChIP experiments revealed low levels of acetylated
histone H4 in untreated HCT116 cells. These levels increased
significantly after treatment with the histone deacetylase inhib-
itor trichostatin A but to a greater extent after MBD2 deple-
FIG. 3. Comparison of MBD2 and DNA methylation levels in the duodenum and the colon. (A) Analysis of global methylation levels in
duodenum (D) and colon (C) as determined by an affinity labeling assay with a HA-tagged poly-MBD domain reagent (16). M.Sss1-methylated
(M) and nonmethylated bacteriophage lambda DNA (U) were positive and negative controls, respectively. The single HA-Co slot contained
immobilized HA-tagged protein as a positive control for the anti-HA monoclonal antibody. (B) Bisulfite genomic sequencing of the Tff2 upstream
region in duodenum and colon. The map shows the promoter region and first exon (open arrow). CpGs are represented by vertical lines. Brackets
show PCR products amplified after bisulfite treatment. Empty circles represent unmethylated cytosine residues, and filled circles represent
methylated cytosine residues. Each line corresponds to a sequenced DNA strand. (C) Bisulfite genomic sequencing of the p48 promoter in the
colon and duodenum of wild-type mice. CpGs are represented by vertical lines. Horizontal lines linked to brackets show PCR products amplified
after bisulfite treatment. Empty squares represent unmethylated cytosine residues, and filled squares represent methylated cytosine residues. Each
row represents a single sequenced DNA molecule, and column height corresponds to the number of strands sequenced (i.e., 14 to 24) for each
PCR product. (D) Western blot analysis for MBD2 and GAPDH in protein extracts from wild-type duodenum, jejunum, ileum, and colon. A
twofold dilution series for each protein extract is shown.
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tion by shRNA and in methylation-deficient DKO cells (Fig.
6C). Bisulfite genomic sequencing of the TFF2 promoter con-
firmed high levels of DNA methylation (90%) in wild-type
HCT116 cells but lower levels in DKO cells (Fig. 5A). The
results demonstrate DNA methylation-dependent binding of
MBD2 to the TFF2 promoter and show elevated histone acet-
ylation in this region when MBD2 is depleted.
DISCUSSION
Our results identify MBD2 as a key regulator of a gene set
that is normally expressed in the duodenum and exocrine pan-
creas but not in the colon. Silencing of these ExPa genes in the
colon depends on MBD2, since in its absence about half of all
mice show expression in this intestinal segment. We found no
evidence that this effect is due to modulation of DNA meth-
ylation, since neither whole genomic DNA nor upstream reg-
ulatory regions of the p48 and Tff2 genes showed obvious
differences in CpG methylation between the colon and the
duodenum. These results imply that differential DNA methyl-
ation is not responsible for the difference, although we cannot
altogether exclude the involvement of variable DNA methyl-
ation at specific genes or in a small subset of intestinal cells.
The concentration of MBD2, on the other hand, was signifi-
cantly higher in the colon than in the duodenum, raising the
possibility that modulation of this repressor could regulate
ExPa gene expression against a background of constant DNA
methylation levels. We tested this idea in the human HCT116
colon cell line and found that depletion of MBD2 indeed
caused activation of several ExPa genes. Since MBD2 is part of
a NuRD complex, which contains histone deacetylases (8, 22),
chromatin hyperacetylation is the expected result of MBD2
loss. Accordingly, loss of MBD2 was accompanied by signifi-
cantly increased histone acetylation at the TFF2 gene. The
results suggest that the high concentration of colonic MBD2
imposes silence on the ExPa genes in this intestinal region,
even though the DNA methylation levels appear to be no
different from those in the duodenum. The levels of MBD2 are
also high in the jejunum and ileum, where ExPa genes remain
silent, but we did not detect derepression of these genes in the
absence of MBD2. The results indicate that MBD2 is not
essential for ExPa gene silencing in these midintestinal regions.
Gene expression analysis along the length of the mouse
intestine has shown that fewer specialized genes are expressed
in the colon than in more proximal regions of the intestinal
tract (4). Little is known about the molecular basis of segmen-
tal gene expression along the intestinal anterior-posterior axis.
One hypothetical possibility is that expression patterns are
regulated by the abundance of specific transcriptional activa-
FIG. 4. Depletion of MBD2 induces ExPa gene expression in a human colon cell line. (A) Real-time RT-PCR analysis for MBD2 expression
levels in a mock-transfected HCT116 cell clone (vector) and two stable derivate cell lines expressing shRNA directed against MBD2 (shMBD2-1
and shMBD2-2). (B) Western blot analysis for MBD2 in cell extracts from mock-transfected cells (vector) and a cell clone expressing shRNA for
MBD2 (shMBD2-2). The structure and length of the MBD2a and MBD2b isoforms is indicated below. (C) Real-time RT-PCR analysis of ExPa
gene expression in control cells and cells stably expressing shRNA against MBD2. Values indicate the overexpression normalized to the vector
control. (D) Moderate (four- to fivefold) reduction of MBD2 mRNA levels by siRNA knockdown in two transfected cell lines si-1 and si-2) and
two mock-transfected control cell lines analyzed by real-time RT-PCR. (E) Western blot analysis of MBD2 isoform confirms partial depletion in
the two siRNA-transfected cell lines. Wild-type levels of MBD2 are seen in control cell lines (Co-1 and Co-2). (F) Real-time RT-PCR analysis of
TFF2 and CEL gene expression levels in control and MBD2-depleted HCT116 cells.
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tors in each segment. An alternative, but not mutually exclu-
sive, possibility is that differential silencing of gene expression
contributes to patterning through segmental variation in the
abundance of transcriptional repressors. Previous work has
indicated that variations in the expression of histone deacety-
lases, which are components of many corepressors, are crucial
for embryonic development of the gastrointestinal tract (33).
The observed anterior-posterior decline in transcriptional
FIG. 5. Activation of ExPa gene expression by depletion of DNA methylation in HCT116 cells. (A) Bisulfite genomic sequencing of the TFF2
promoter shows reduced DNA methylation in methylation-deficient HCT116 cells carrying mutations in DNMT1 and DNMT3 (DKO cells) compared
to wild-type HCT116 cells. CpGs are represented by vertical lines. Dotted lines show PCR products amplified after bisulfite treatment. Empty circles
represent unmethylated cytosine residues, and filled circles represent methylated cytosine residues. (B) Real-time RT-PCR for ExPa genes in wild-type
HCT116 and DKO cells. (C) Bisulfite genomic sequencing of the p48 promoter CpG island shows dense CpG methylation in HCT116 cells but not in
DKO cells or human blood. CpGs are represented by vertical lines. The bracket (Bis) shows PCR products amplified after bisulfite treatment.
FIG. 6. MBD2 binds to the TFF2 in a DNA methylation-dependent manner and reduces histone H4 acetylation levels. (A) Diagram indicating the
location of CpG sites (vertical lines) and the TFF2 upstream fragments amplified by primer pairs A, B, and C. (B) ChIP shows reduced binding of MBD2
in regions A to C of the TFF2 promoter after either MBD2 depletion by RNA interference or depletion of DNA methylation in DNA methyltransferase
mutant DKO cells. (C) Increased histone H4 acetylation after depletion of MBD2 or DNA methylation. ChIP analysis for panacetylated histone H4 at
the TFF2 promoter was carried out with chromatin from wild-type and TSA-treated HCT116 cells, HCT116 cells expressing shRNA against MBD2, and
DKO cells. Negative control immunoprecipitations in panels B and C (Co) were performed with an unrelated antibody (anti-	-amylase).
VOL. 27, 2007 MBD2 AND GUT TRANSCRIPTION PATTERNS 4055
complexity along the intestine (4) could therefore be caused by
increased cellular concentrations of broad specificity repres-
sors in posterior intestinal segments.
We were initially prompted to study ExPa gene expression
through an interest in the resistance of Mbd2-null mice to
intestinal tumorigenesis in the Min mouse model (32). It is
unlikely that our findings are relevant to this phenotype, how-
ever, for two major reasons. First, most adenomatous polyps in
the Min mouse arise in the proximal intestinal tract (25), where
we detected no altered expression of the ExPa genes. The
location of ExPa gene mis-expression and the sites of tumori-
genesis therefore do not match. Second, ExPa gene expression
is not seen in all mice, whereas the tumor resistance phenotype
appears fully penetrant. If failure to overexpress the ExPa
genes abolished tumor resistance in mice, then a subset of
animals (about half) with normal tumor susceptibility would
have been detected. The absence of such a subset suggests that
overexpression of ExPa genes is not causally related to tumor
resistance. It is possible that other genes that are more subtly
misregulated in the Mbd2-null intestine are relevant to the
latter phenotype.
A puzzling feature of the colon phenotype is its incomplete
penetrance. A continuum of ExPa gene expression levels is
observed, ranging from very high (equivalent to duodenum) to
no detectable expression in about half of the animals. It is
common for transcriptional repressors to contribute to silenc-
ing as part of a redundant set of silencing mechanisms, and this
can cause partial gene activation in a stochastic manner when
one component is absent. Leakproof inactivation of genes on
one X chromosome in female mammals, for example, relies on
layered epigenetic silencing mechanisms, each of which re-
duces the probability per cell of gene reactivation (6). Indeed,
MBD2 itself is not solely responsible for silencing of the inter-
leukin-4 gene in TH cells, since not all MBD2-deficient TH cells
express the gene (13). In spite of these precedents at the
cellular level, variability of gene reactivation between members
of an inbred population of mice is unexpected. Our studies
make it unlikely that age, gender, or genetic background are
critical factors affecting penetrance (see Results). Instead, they
suggest that stochastic variation arises during development.
We speculate that stem cells at the base of the colon crypts are
variably dependent on MBD2 for silencing the ExPa genes in
their differentiated descendants. MBD2 dependence or inde-
pendence would be a stable feature that affects a particular
crypt for the lifetime of its parent stem cell.
Mbd2-null animals that express ExPa genes showed coinci-
dent upregulation of p48. The p48 polypeptide is a component
of Ptf1, a trimeric transcription factor that is essential for the
development and maintenance of the differentiated state of the
exocrine pancreas. A CpG island is located near the transcrip-
tion start site of p48, which, like many CpG islands at highly
tissue specifically expressed genes, is nonmethylated regardless
of gene activity, except in cultured cell lines where aberrant
methylation occurs. In view of its pivotal role in differentiation
of the exocrine pancreas, we suspected that inappropriate p48
expression in the Mbd2-null colon is a trigger for ExPa gene
expression. Under a simple hypothetical pathway, MBD2
would directly mediate repression of p48 in the colon. Al-
though the p48 promoter is associated with a constitutively
nonmethylated CpG island, which therefore should not bind
MBD2, studies of the sequence requirements of p48 gene ex-
pression in mouse acinar and nonpancreatic cells have impli-
cated a region extending up to 7 kb upstream of the p48
transcription start site in both positive and negative regulation
of gene activity (18, 30). This region is not within the CpG
island region and, accordingly, bisulfite sequence analysis in
duodenum and colon detects CpG methylation. Also, MBD2 is
bound to the equivalent region of human P48 by ChIP in
HCT116 cells (data not shown). Taken together, our results
are compatible with the hypothesis that the p48 gene is under
direct regulatory control by MBD2.
MBD2 deficiency in HCT116 cells, which have silenced P48
via aberrant CpG island methylation, induced TFF2 and CEL,
but not RIB1 or ELA2. Both RIB1 and ELA2 possess CpG-
deficient promoters that do not correspond to CpG islands.
The different behaviors of these genes in HCT116 cells and
mouse colon could be explained if TFF2 and CEL are direct
targets for MBD2 repression, whereas the induction of RIB1
and ELA2 requires the upstream expression of P48. In line
with this hypothesis, the PTF1 transcriptional activator com-
plex, which includes P48, has been shown to bind an enhancer
of the ELA2 gene (29). Also, we show that MBD2 is associated
with the TFF2 promoter region in HCT116 cells, and its ab-
sence is accompanied by alterations in the structure of TFF2
chromatin. Interestingly, a transgenic mouse with a reporter
gene under the control of the multimerized Ela2 enhancer
showed expression in the pancreas, duodenum and colon (29).
It is conceivable that the absence of appropriate DNA meth-
ylation in the transgene prevented recruitment of MBD2,
thereby permitting expression in the colon.
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